Genzyme, one of the world leaders in medical biotechnology and a subsidiary of Sanofi since 2011, will be opening a new bioproduction platform in Lyon-Gerland in 2016, in partnership with Transgène, a subsidiary of Institut Mérieux.

 

Construction of this €10 million structure of 1200 square meters are planned to start in June 2014. The platform will produce batches of active compounds for the immunotherapy products of Transgène, including treatments for certain types of lung cancer. Products from this production line will start selling in 2018.

 

Sanofi is the owner of the platform and Transgène will be the prime client for a period of 15 years. Other clients will also have access to the advanced technology of the facility to develop viral therapies. “The capacity of the platform can be doubled, if needed,” explained Stéphane Piquand, Director of the industrial sites of Genzyme Lyon.

 

Until then, the Lyon base of Genzyme, which manufactures Thymoglobuline (850,000 vials in 2013), an active compound to prevent the rejection of transplanted organs, also used in hematology, will double its production line in 2015. In ten years, Sanofi, which chose to make Lyon one of its principal production and research platforms in Europe, has invested €1.5 billion in the region. It is now the number one private-sector employer in the Lyon area, with 6,500 employees, including 250 at Genzyme.